Publikasjoner
NIBIOs ansatte publiserer flere hundre vitenskapelige artikler og forskningsrapporter hvert år. Her finner du referanser og lenker til publikasjoner og andre forsknings- og formidlingsaktiviteter. Samlingen oppdateres løpende med både nytt og historisk materiale. For mer informasjon om NIBIOs publikasjoner, besøk NIBIOs bibliotek.
2023
Forfattere
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenSammendrag
Det er ikke registrert sammendrag
Forfattere
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenSammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Forfattere
Heidi Udnes Aamot Silje Kvist Simonsen Magne Nordang Skårn Katherine Ann Gredvig Nielsen Birgitte Henriksen Guro BrodalSammendrag
Det er ikke registrert sammendrag
Forfattere
Hang Su Andre van Eerde Espen Rimstad Ralph Bock Norica Branza-Nichita Igor A. Yakovlev Jihong Liu ClarkeSammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Forfattere
Tage Thorstensen Johanna Eva Bodin Nur Duale Johan Johansen Volha Shapaval Øystein Sæle Anne-Marthe Ganes Jevnaker Ville Erling Sipinen Kristian Prydz Kaja Helvik SkjærvenSammendrag
Det er ikke registrert sammendrag
Forfattere
May Bente BrurbergSammendrag
Det er ikke registrert sammendrag
Forfattere
Ana-Maria Madalina Pantazica Andre van Eerde Mihaela-Olivia Dobrica Iuliana Caras Irina Ionescu Adriana Costache Catalin Tucureanu Hege Særvold Steen Catalin Lazar Inger Heldal Sissel Haugslien Adrian Onu Crina Stavaru Norica Branza-Nichita Jihong Liu ClarkeSammendrag
The recent SARS-CoV-2 pandemic has taught the world a costly lesson about the devastating consequences of viral disease outbreaks but also, the remarkable impact of vaccination in limiting life and economic losses. Vaccination against human Hepatitis B Virus (HBV), a major human pathogen affecting 290 million people worldwide, remains a key action towards viral hepatitis elimination by 2030. To meet this goal, the development of improved HBV antigens is critical to overcome non-responsiveness to standard vaccines based on the yeast-produced, small (S) envelope protein. We have recently shown that combining relevant immunogenic determinants of S and large (L) HBV proteins in chimeric antigens markedly enhances the anti-HBV immune response. However, the demand for cost-efficient, high-quality antigens remains challenging. This issue could be addressed by using plants as versatile and rapidly scalable protein production platforms. Moreover, the recent generation of plants lacking β-1,2-xylosyltransferase and α-1,3-fucosyltransferase activities (FX-KO), by CRISPR/Cas9 genome editing, enables production of proteins with “humanized” N-glycosylation. In this study, we investigated the impact of plant N-glycosylation on the immunogenic properties of a chimeric HBV S/L vaccine candidate produced in wild-type and FX-KO Nicotiana benthamiana. Prevention of β-1,2-xylose and α-1,3-fucose attachment to the HBV antigen significantly increased the immune response in mice, as compared with the wild-type plant-produced counterpart. Notably, the antibodies triggered by the FX-KO-made antigen neutralized more efficiently both wild-type HBV and a clinically relevant vaccine escape mutant. Our study validates in premiere the glyco-engineered Nicotiana benthamiana as a substantially improved host for plant production of glycoprotein vaccines.
Forfattere
Belachew Asalf TadesseSammendrag
Det er ikke registrert sammendrag